Trevi Therapeutics TRVI Stock
Trevi Therapeutics Price Chart
Trevi Therapeutics TRVI Financial and Trading Overview
| Trevi Therapeutics stock price | 2.94 USD |
| Previous Close | 2.53 USD |
| Open | 2.59 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.46 - 2.61 USD |
| 52 Week Range | 1.43 - 4.68 USD |
| Volume | 167.44K USD |
| Avg. Volume | 263.42K USD |
| Market Cap | 154.98M USD |
| Beta (5Y Monthly) | 0.735264 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.33 USD |
TRVI Valuation Measures
| Enterprise Value | 49.73M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.9999995 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.5230224 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.636 |
Trading Information
Trevi Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.735264 |
| 52-Week Change | 27.72% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.68 USD |
| 52 Week Low | 1.43 USD |
| 50-Day Moving Average | 2.55 USD |
| 200-Day Moving Average | 2.28 USD |
TRVI Share Statistics
| Avg. Volume (3 month) | 263.42K USD |
| Avg. Daily Volume (10-Days) | 269.3K USD |
| Shares Outstanding | 60.07M |
| Float | 17.85M |
| Short Ratio | 0.5 |
| % Held by Insiders | 3.62% |
| % Held by Institutions | 83.39% |
| Shares Short | 242.64K |
| Short % of Float | 0.58% |
| Short % of Shares Outstanding | 0.40% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.96% |
| Return on Equity (ttm) | -50.31% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -30394000 USD |
| Net Income Avi to Common (ttm) | -28224000 USD |
| Diluted EPS (ttm) | -0.27 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 111.26M USD |
| Total Cash Per Share (mrq) | 1.85 USD |
| Total Debt (mrq) | 9.02M USD |
| Total Debt/Equity (mrq) | 8.86 USD |
| Current Ratio (mrq) | 8.651 |
| Book Value Per Share (mrq) | 1.694 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -29280000 USD |
| Levered Free Cash Flow (ttm) | -19639624 USD |
Profile of Trevi Therapeutics
| Country | United States |
| State | CT |
| City | New Haven |
| Address | 195 Church Street |
| ZIP | 06510 |
| Phone | 203-304-2499 |
| Website | https://www.trevitherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Q&A For Trevi Therapeutics Stock
What is a current TRVI stock price?
Trevi Therapeutics TRVI stock price today per share is 2.94 USD.
How to purchase Trevi Therapeutics stock?
You can buy TRVI shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Trevi Therapeutics?
The stock symbol or ticker of Trevi Therapeutics is TRVI.
Which industry does the Trevi Therapeutics company belong to?
The Trevi Therapeutics industry is Biotechnology.
How many shares does Trevi Therapeutics have in circulation?
The max supply of Trevi Therapeutics shares is 68.49M.
What is Trevi Therapeutics Price to Earnings Ratio (PE Ratio)?
Trevi Therapeutics PE Ratio is now.
What was Trevi Therapeutics earnings per share over the trailing 12 months (TTM)?
Trevi Therapeutics EPS is -0.29 USD over the trailing 12 months.
Which sector does the Trevi Therapeutics company belong to?
The Trevi Therapeutics sector is Healthcare.
Trevi Therapeutics TRVI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}